MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$796,197K
Net Income
$69,614K
Net Profit Margin
8.74%
EPS
$0.18
Unit: Thousand (K) dollars
Revenue Breakdown
Oral Solid
Central Nervous System
Distribution Service
Others
Revenue Breakdown
Oral Solid
Central Nervous System
Distribution Service
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net revenue
796,197
722,519
814,319
784,513
Cost of goods sold
461,689
402,406
517,129
510,539
Gross profit
334,508
320,113
297,190
273,974
Selling, general and administrative
148,722
138,860
146,458
137,815
Research and development
39,017
38,383
34,819
63,352
In-process research and development impairment charges
-
-
0*
-
Intellectual property legal development expenses
2,087
1,542
1,411
2,437
Acquisition costs
7,600
5,153
-
-
Restructuring and other charges
554
650
2,470
143
Charges (credit) related to legal matters, net
-8,057
-694
0*
0
Other operating income
1,298
6,941
1
117
Operating income
129,769
141,772
112,033
70,344
Interest expense, net
-55,043
-53,361
-56,237
-62,814
Foreign exchange (gain) loss, net
-1,950
-7,800
-1,437
-3,431
Gain on refinancing
0
-3,510
0
-31,365
Increase in tax receivable agreement liability
-2,439
2,333
-12,289
20,808
Other income, net
653
742
13,165
1,235
Total other expense, net
-58,779
-61,596
-56,798
-75,567
Income before income taxes
70,990
80,176
55,235
-5,223
Provision for income taxes
1,376
2,176
5,662
-23,355
Net income
69,614
78,000
49,573
18,132
Less net income attributable to non-controlling interests
-
-
55,876
-
Net income (loss) attributable to amneal pharmaceuticals, inc
-
-
-6,303
-
Basic EPS
0.18
0.2
-0.02
0.01
Diluted EPS
0.18
0.19
-0.019
0.01
Basic Average Shares
319,200,000
316,023,000
314,507,000
314,168,000
Diluted Average Shares
328,102,000
328,933,000
328,142,000
324,754,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Oral Solid
$175,172K
(-1.73%↓ Y/Y)
Other Dosage Forms
$81,594K
(19.67%↑ Y/Y)
Transdermal
$67,038K
(64.67%↑ Y/Y)
Ephinephrine Auto Injector
$62,214K
(-6.58%↓ Y/Y)
Injectable
$56,783K
(63.89%↑ Y/Y)
Biosimilar
$29,128K
(15.37%↑ Y/Y)
Oral Liquid
$10,371K
(-41.99%↓ Y/Y)
Central Nervous System
$95,344K
(14.29%↑ Y/Y)
Hormonal Allergy
$42,099K
(18.86%↑ Y/Y)
Other Therapeutic
Classes
$11,852K
(36.23%↑ Y/Y)
Subtotal Dosage Forms
$482,300K
(11.77%↑ Y/Y)
International
$7,613K
(300.47%↑ Y/Y)
Distribution Service
$86,930K
(-12.78%↓ Y/Y)
Government Label
$50,207K
(10.54%↑ Y/Y)
Institutional
$12,112K
(19.54%↑ Y/Y)
Product And Service
Other
$7,740K
(-1.11%↓ Y/Y)
Revenue From Contract
With Customer...
$149,295K
Affordable Medicines
Segment
$489,913K
(24668.10%↑ Y/Y)
Av KARESegment
$156,989K
(-3.71%↓ Y/Y)
Specialty Segment
$149,295K
(16.60%↑ Y/Y)
Net revenue
$796,197K
(9.89%↑ Y/Y)
Gross profit
$334,508K
(16.86%↑ Y/Y)
Other operating
income
$1,298K
Cost of goods sold
$461,689K
(5.35%↑ Y/Y)
Operating income
$129,769K
(16.52%↑ Y/Y)
Selling, general and
administrative
$148,722K
(19.68%↑ Y/Y)
Research and development
$39,017K
(-18.65%↓ Y/Y)
Charges (credit)
related to legal...
-$8,057K
(-2165.90%↓ Y/Y)
Acquisition costs
$7,600K
Intellectual property legal
development expenses
$2,087K
(3.47%↑ Y/Y)
Restructuring and other
charges
$554K
(-45.90%↓ Y/Y)
Income before income
taxes
$70,990K
(37.28%↑ Y/Y)
Total other expense,
net
-$58,779K
(1.48%↑ Y/Y)
Other income, net
$653K
(-59.29%↓ Y/Y)
Net income
$69,614K
(95.49%↑ Y/Y)
Provision for income taxes
$1,376K
(-91.45%↓ Y/Y)
Interest expense, net
-$55,043K
(15.45%↑ Y/Y)
Increase in tax
receivable agreement...
-$2,439K
(44.82%↑ Y/Y)
Foreign exchange (gain)
loss, net
-$1,950K
(-123.62%↓ Y/Y)
Buy us a coffee
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)